NorthSea: Engineering fatty acids for NASH

NorthSea’s structurally engineered fatty acids hit on key NASH mechanisms

With its structurally engineered fatty acid platform and a candidate that can hit the three primary mechanisms behind NASH, NorthSea thinks it can succeed in the hepatic and cardiometabolic disease space where so many others have failed.

NorthSea Therapeutics B.V. announced a $40 million series B round on Wednesday led by venBio Partners. Fellow new investor Sofinnova Investments also joined existing investors Forbion, Novo Seeds, New Science Ventures and BioGeneration

Read the full 702 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE